Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-07-16
2008-09-02
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S316000, C514S317000, C514S318000, C540S597000, C546S194000, C546S207000, C546S208000
Reexamination Certificate
active
07419990
ABSTRACT:
Certain novel piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
REFERENCES:
patent: 6166037 (2000-12-01), Budhu et al.
patent: 6818658 (2004-11-01), Ujjainwalla et al.
patent: WO 02/067869 (2002-09-01), None
patent: WO 02/068387 (2002-09-01), None
patent: WO 02/068388 (2002-09-01), None
patent: WO 03/009847 (2003-02-01), None
Banno et al. “The melanocortin agonist . . . ” Petides 25, p. 1279-1286 (2004).
Obici et al. “Central melanocortin receptor . . . ” J. Clin. Invest. 108, p. 1079-1085 (2001).
Pierroz et al. “Effects of acute . . . ” diabetes, 51, p. 1337-1345 (2002).
Pochopin et al. “Amino acid derivatives . . . ” Int. J. Pharm. 121, p. 157-167 (1995).
Kopelman, Nature, vol. 404 (2000), pp. 635-643, “Obesity as a medical problem”.
Huszar et al., Cell, vol. 88 (1997), pp. 131-141, “Targeted disruption of the melanocortin-4 receptor results in obesity in mice”.
Kask et al., Biochem. & Biophys. Res. Comm., vol. 245 (1998), pp. 90-93, “Selected antagonist for the melanocortin 4 receptor (HSO014) increases food intake in free-feeding rats”.
Chen et al., Cell, vol. 91 (1997), pp. 789-798, “Exocrine gland dysfunction in MC5-R-deficient mice . . . ”.
Giraudo et al., Brain Res., vol. 809 (1998), pp. 302-306, “Feeding effects of hypothalamic injection of melanocortin 4 receptor ligands”.
Hill et al. Science, vol. 280 (1998), pp. 1371-1374, “Environmental contributions to the obesity epidemic”.
Corcos et al., Society for Neuroscience Abstracts, vol. 23 (1997), Abstract No. 267.9, p. 673, “HP 228 is a potent agonist of melanocortin receptor 4, and significantly attenuates obesity and diabetes in Zucker fatty rats”.
Peptides: Frontiers of Peptide Science, Proceedings of the 15th American Peptide Symposium, Jun. 14-19, 1997, Nashville, TN.
Wessels et al., J. of Urology, vol. 160 (1998), pp. 389-393, “Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction . . . ”.
Dorr et al., Life Sciences, vol. 58, No. 20 (1996), pp. 1777-1784, “Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study”.
Wessells et al., Urology, vol. 56 (2000), pp. 641-646, “Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction”.
Graul, Drugs News & Perspectives, vol. 9 (1996), pp. 572-575, “Latest findings on the diagnosis and treatment of erectile dysfunction”.
Dinsmore et al., Brit. Med. J., vol. 318 (1999), pp. 387-390, “ABC of sexual health—erectile dysfunction”.
Gingell et al., Exp. Opin. Ther. Patents, vol. 9 (1999), pp. 1689-1696, “Emerging pharmacological therapies for erectile dysfunction”.
Yoram et al., Current Opinion in Urology, vol. 7 (1997), pp. 349-353, “Oral pharmacotherapy in erectile dysfunction”.
Heaton et al., Int'l J. of Impotence Res., vol. 9 (1997), pp. 115-121, “A therapeutic taxonomy of treatments for erectile dysfunction: an evolutionary imperative”.
Budhu et al., Database Caplus on STN No. 130:223167 (1999), “Preparation of piperidinylpyrrolidins as modulators of chemokine receptor activity”.
Goulet et al., Database Caplus on STN No. 137:216872 (2002), “Acylated piperidine derivatives, specifically 1-[(aminocycloalkyl)carbonyl]piperidines, as melanocortin-4 receptor agonists, and their pharmaceutical . . . ”.
Sings Heather
Ujjainwalla Feroze
Billups Richard C.
Brown Baerbel R.
Chang Celia
Fitch Catherine D.
Merck & Co. , Inc.
LandOfFree
Piperidine derivatives as melanocortin-4 receptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperidine derivatives as melanocortin-4 receptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperidine derivatives as melanocortin-4 receptor agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3973886